Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7644495 | 0.89 | MAPT (0.41) | CYP1A2MAPK1PKMRAB9AKDM4E | |
| SCHEMBL3760394 | 0.83 | ALDH1A1 (0.49) | CYP1A2MAPK1KDM4EALDH1A1KMT2A | |
| SCHEMBL6775866 | 0.83 | CYP1A2 (0.49) | CYP1A2MAPK1RAB9AALDH1A1MAPT | |
| SCHEMBL27289329 | 0.82 | FBP1 (0.51) | CYP1A2MAPK1PKMRAB9AKDM4E | |
| SCHEMBL1224216 | 0.80 | CYP1A2 (0.69) | CYP1A2MAPK1PKMRAB9AKDM4E | |
| SCHEMBL2813817 | 0.80 | CYP1A2 (0.69) | CYP1A2MAPK1PKMRAB9AKDM4E | |
| SCHEMBL6784812 | 0.80 | MEN1 (0.48) | CYP1A2MAPK1PKMRAB9AALDH1A1 | |
| SCHEMBL6779809 | 0.80 | MEN1 (0.52) | MAPK1RAB9AKDM4EALDH1A1KMT2A | |
| SCHEMBL27875770 | 0.79 | CYP1A2 (0.67) | CYP1A2MAPK1PKMRAB9AKDM4E | |
| SCHEMBL6775069 | 0.79 | ALDH1A1 (0.56) | RAB9AKDM4EALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825191-B2 | ANTICOAGULANT | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030186969-A1 | Benzodiazepine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1329450-A1 | BENZODIAZEPINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186969-A1 | Benzodiazepine derivatives | GABRA1, F11, GABRA4 | CYP1A2 61/4885MAPK1 1817/4885PKM 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.